Bio-Techne Corporation (TECH) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bio-Techne Corporation (TECH:NASDAQ), powered by AI.

Current Price
$54.00
P/E Ratio
115.9
Market Cap
8.5B
Sector
Healthcare
What is the Bio-Techne Corporation stock price forecast?

Bio-Techne Corporation is currently trading at $54.00. View real-time AI analysis on Alpha Lenz.

What is Bio-Techne Corporation insider trading activity?

View the latest insider trading data for Bio-Techne Corporation on Alpha Lenz.

What is Bio-Techne Corporation's P/E ratio?

Bio-Techne Corporation's P/E ratio is 115.9.

Bio-Techne Corporation

NASDAQ · TECH
$54.00-0.02(-0.04%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Bio-Techne Corporation's future dividend policy...
Alpha Chat Insight

Bio-Techne Corporation trades at a P/E of 115.9 (premium valuation) with modest ROE of 3.7%.

Ask for details

Company Overview

Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing an extensive range of biotechnological tools that support the advancement of life sciences. Key offerings include proteins, antibodies, assay kits, and laboratory services critical for scientific research and drug development. Bio-Techne operates across diverse sectors such as biotechnology, pharmaceuticals, academic research, and healthcare, supplying innovative solutions that facilitate groundbreaking research and therapeutic discoveries. Its products are essential in advancing modern biology and medicine, contributing to significant developments in areas like cancer research, immunology, and cell biology. Bio-Techne’s commitment to innovation and quality makes it a pivotal player in the biotechnology industry, elevating scientific discovery and fostering advancements in personalized medicine and diagnostics. With a strong global presence, Bio-Techne continues to impact the global life sciences landscape profoundly, upholding a legacy of excellence and reliability in the biotechnological sector.

CEOMr. Kim Kelderman
SectorHealthcare
IndustryBiotechnology
Employees3,100

Company Statistics

FY 2025

Profile

$8.51BMarket Cap
$1.22BRevenue
0.00Shares Out
3,100Employees

Margins

64.80%Gross
29.32%EBITDA
19.91%Operating
8.07%Pre-Tax
6.02%Net

Valuation

115.89P/E
4.43P/B
6.97EV/Sales
24.58EV/EBITDA
33.16P/FCF

Growth (CAGR)

3.33%Rev 3Yr
10.55%Rev 5Yr
-6.37%Op Inc 3Yr
10.28%Op Inc 5Yr
-34.66%Net Inc 3Yr
-20.37%Net Inc 5Yr

Returns

2.79%ROA
3.68%ROE
4.07%ROIC

Financial Health

$162.19MCash & Cash Equivalents
$476.87MNet Debt
33.31%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Bio-Techne Corporation (ticker: TECH) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 3,100 employees. Market cap is $8.5B.

The current price is $54 with a P/E ratio of 115.89x and P/B of 4.43x.

ROE is 3.68% and operating margin is 19.91%. Annual revenue is $1.2B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Bio-Techne Corporation (TECH) Stock Forecast 2026 $54.00 — Price, Financials & Analyst Targets | Alpha Lenz